CAR-T细胞治疗在急性髓系白血病中的研究和应用进展

Research and application progress of CAR T-cell therapy in acute myeloid leukemia

急性髓系白血病(acute myeloid leukemia,AML)是一种高度异质性的恶性血液病,近些年随着化疗、靶向药物和造血干细胞移植的发展,AML患者的疗效已有较大的提高,但总体而言,绝大部分患者仍无法治愈。目前,成人AML患者5年生存率仍未超过30%。嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在复发难治性B淋巴细胞肿瘤领域取得了显著疗效,越来越多的研究开始研发CAR-T疗法在其他类型肿瘤及疾病中的应用。本文主要就近些年CAR-T疗法在AML中的临床应用和研究进展做出综述。

Acute myeloid leukemia(AML)is a highly heterogeneous hematologic malignancy.In recent years,with the development of chemotherapy,targeted drugs,and hematopoietic stem cell transplantation,the efficacy of treatment for patients with AML has greatly improved;however,most patients remain incurable.The 5-year survival rate of adult patients with AML remains<30%.The efficacy of chimeric antigen receptor(CAR)T-cell therapy for relapsed and refractory B-lymphocyte tumors has been significant,and an increasing number of studies have begun developing the application of CAR T-cell therapy for other types of tumors and diseases.This study reviews the clinical application and research progress of CAR T-cell therapy for AML in recent years.